News
TNXP
0.1568
+0.90%
0.0014
Weekly Report: what happened at TNXP last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at TNXP last week (0408-0412)?
Weekly Report · 04/15 11:31
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
Benzinga · 04/11 14:09
Analysts Are Bullish on These Healthcare Stocks: Tonix Pharma (TNXP), OrganiGram Holdings (OGI)
TipRanks · 04/11 12:02
Weekly Report: what happened at TNXP last week (0401-0405)?
Weekly Report · 04/08 11:36
TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q4 2023
Tonix Pharmaceuticals reported earnings per share of -86 cents for the fourth quarter of 2023. The company reported revenue of $3.78 million. This was 1.33% worse than the analyst estimate for revenue. Tonix reported results for the quarter of 1923.
Investorplace · 04/02 03:52
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended in December - Earnings Summary
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 86 cents per share. Revenue was $3.78 million; analysts expected a loss of $27.32 million. The shares of Tonix Holding Corp have lost 53.8% this year.
Reuters · 04/01 22:09
Tonix Pharmaceuticals GAAP EPS of -$0.86, revenue of $3.78M
Tonix Pharmaceuticals Holding Corp. Reported Q4 GAAP EPS of -$0.86, revenue of $3.78M. As of December 31, 2023, Tonix had approximately $24.9 million of cash and cash equivalents. The company had inventory of $13.6 million at the end of the quarter.
Seeking Alpha · 04/01 20:38
Tonix Pharmaceuticals Q4 EPS $(0.86) Beats $(1.55) Estimate, Sales $3.80M Miss $5.75M Estimate
Tonix Pharmaceuticals reported quarterly losses of $0.86 per share. The company reported quarterly sales of $3.80 million which missed the analyst consensus estimate of $5.75 million. Tonix also reported a 75.43 percent increase in sales from the same period last year.
Benzinga · 04/01 20:28
*Tonix Pharmaceuticals 4Q Rev $3.78M >TNXP
Dow Jones · 04/01 20:17
TONIX PHARMACEUTICALS HOLDING CORP - NET LOSS AVAILABLE TO COMMON STOCKHOLDERS WAS $27.3 MLN, OR $0.86 PER SHARE, BASIC AND DILUTED, FOR Q4 2023
Reuters · 04/01 20:15
Press Release: Tonix Pharmaceuticals Reports -3-
Tonix is developing potential broad-spectrum antiviral drugs in three programs. The DoD announced in 2020 it is seeking broad spectrum drugs. The company has completed the transition to becoming a fully integrated pharmaceutical company. Tonix's product candidates are investigational new drugs or biologics.
Dow Jones · 04/01 20:15
*Tonix Pharmaceuticals 4Q Loss/Shr 86c >TNXP
Dow Jones · 04/01 20:15
Press Release: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya(TM) for NDA submission second half of 2024. Pre-NDA meeting with FDA scheduled for second quarter 2024. Commercial planning underway for U.S. Launch of Ton mya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia.
Dow Jones · 04/01 20:15
Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares traded lower by 7.2% to $0.17 Monday morning. The company announced the pricing of a $4.4 million registered direct offering last week. Tonix shares hit a new-all time low.
Benzinga · 04/01 14:43
Weekly Report: what happened at TNXP last week (0325-0329)?
Weekly Report · 04/01 11:32
12 Health Care Stocks Moving In Friday's Intraday Session
Avalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The company's market cap stands at $510.4 million. Nexalin Technology shares moved upwards by 83.33% and Biodexa Pharmaceuticals stock increased by 81.6%. Losers include Tonix Pharmaceuticals and Kodiak Sciences.
Benzinga · 03/29 16:30
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 03/28 18:08
Why Tonix Pharmaceuticals Stock (TNXP) Is Getting Obliterated
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares are trading lower by 33.9% to $0.22 Thursday afternoon. The company announced pricing of a $4.4 million registered direct offering. The offering is expected to generate gross proceeds of approximately $3.5 million.
Benzinga · 03/28 17:02
More
Webull provides a variety of real-time TNXP stock news. You can receive the latest news about Tonix Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.